Over 850 Cleansweep Auctions End Tomorrow 06/13 - Bid Now
Over 1050 Total Lots Up For Auction at One Location - NJ 06/14

Varian gets market nod for Halcyon and Ethos radiotherapy platforms with HyperSight CBCT

by John R. Fischer, Senior Reporter | February 08, 2023
Rad Oncology
Varian's Halcyon radiotherapy platform (Photo courtesy of Varian)
Varian has received an FDA clearance and CE mark for its Halcyon and Ethos radiotherapy systems with HyperSight imaging, which enables the calculating of radiation dose distribution on cone-beam CT images to adapt and improve treatment.

HyperSight calculates dose during treatment, eliminating the need for patients to undergo a separate CT scan for simulation and planning. This widens the potential to adapt treatment based on anatomical changes to tumors and surrounding organs, which can occur day-to-day during each radiation course.

Additionally, HyperSight’s CBCT technology produces larger images with better contrast and is 10 times faster than conventional linac imaging systems.

Siemens Healthineers acquired Varian in 2021 for $16.4 billion, marking the former’s return to the radiotherapy market after more than a decade.

An image-guided volumetric intensity modulated radiotherapy system, the Halcyon platform was cleared by the FDA in June 2017 and modulates the radiation beam when targeting tumors.

The Ethos system was cleared in 2020 and utilizes AI to adapt treatment based on changes in patient anatomy and tumor shape and position, at the time of treatment. It facilitates treatment within 15 minutes, from patient setup through treatment delivery.

Following its clearance by the FDA, the Halcyon system with HyperSight was used for the first time on a cancer patient at Penn Medicine.

You Must Be Logged In To Post A Comment